Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bmj.j1592 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Cell
November 2018
Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Department of Medicine, Massachusetts General Hospital, HMS, Boston, MA, USA. Electronic address:
Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of patients succumb to disease. To identify factors associated with success or failure of checkpoint therapy, we profiled transcriptomes of 16,291 individual immune cells from 48 tumor samples of melanoma patients treated with checkpoint inhibitors.
View Article and Find Full Text PDFA phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.
Oncoimmunology
February 2018
Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.
: Approximately 50% of melanomas harbor BRAF mutations. Treatment with BRAF +/- MEK inhibition is associated with favorable changes in the tumor microenvironment thus providing the rationale for combining targeted agents with immunotherapy. : Patients with unresectable Stage III or IV BRAF mutant melanoma were enrolled in a single-center prospective study (n = 6).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!